[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"colonisation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:colonisation":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":5},"100644401","tackling-resistance-and-healthcare-economics-through-cpe-screening-100644401",false,"NCT07663110","Tackling Resistance And HealthCare Economics Through CPE Screening","Multi-centre Evaluation of Carbapenemase-producing Enterobacterales (CPE) Prevalence and Transmission Dynamics, Recommendations on Screening Strategies, and Health Economics Outcomes Research Impact to Inform Policy Change","TRACE-CPE","Inclusion Criteria:\n\n* All adult (18 years or older) medical patients admitted to the acute medical unit during the implementation period who undergo routine rectal CPE testing as per local Trust policy and test positive for CPE colonisation through either the rapid test or culture-based methods.\n\nExclusion Criteria:\n\n* Patient refusal for rectal screening or\n* Clinical contraindication to rectal swab collection","ALL","18 Years",{"count":20,"type":21},16000,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical study is to learn if it is possible to reduce the spread of resistant bacteria called CPEs (Carbapenemase producing Enterobacterales) between patients admitted to hospital.\n\nCPEs can be carried in the gut of people without making them ill. Normally when patients come into hospital, they may undergo a swab test on their bottom to see if CPEs can be grown. This test can take up to 24 hours to produce a result.\n\nThe investigators want to use a faster test which takes 2 hours to produce a result, and whether this can make a difference to CPE spread between person to person.\n\nThe main questions it aims to answer are:\n\n1. Why do people carry, transmit or get infected with CPE?\n2. If a faster test was used to look for CPE, would this be better at reducing patient spread in hospital?\n3. Is a faster test also more cost effective?\n\nParticipants will:\n\n1. Be tested by both the usual and faster test when they come into hospital by a swab on their bottom\n2. Where they test positive for CPE they will be asked to answer some questions about their health",[27,28],"Carbapenem-Resistant Enterobacteriaceae","Colonisation",[30,31,32,33,34,35,36,37],"infection prevention and control","health economics","rapid molecular diagnostics","carbapenem-resistant Enterobacterales","CPEs","CROs","MDROs","hospital transmission","NOT_YET_RECRUITING","2026-06-16",{"date":41,"type":42},"2026-06-23","ACTUAL",{"date":44,"type":21},"2026-08-01",{"date":46,"type":21},"2028-03-31",{"name":48,"class":49},"Imperial College London","OTHER",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":17,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":4},"100626772","phase-1-encapsulated-probiotics--gut-microbiota-100626772","NCT07439978","Encapsulated Probiotics & Gut Microbiota","A Physiological Study of a Fermented Yogurt Drink Containing Probiotics","Probiotics","Inclusion Criteria:\n\n* Capacity to obtain and sign informed consent before any study-related procedure\n* BMI range 18.5-31.9 kg\u002Fm2\n* Willing to abstain from regular consumption of probiotic supplements or food products containing probiotic bacteria (including fermented food and beverages).\n* Willing to abstain from regular consumption of supplements and medications known to alter gastrointestinal function or inflammatory status during the study.\n\nExclusion Criteria:\n\nParticipants who meet any of the following criteria will be excluded:\n\n* Smoking\n* Substance abuse\n* Pregnancy\n* Diagnosis of type 1 and\u002For type 2 diabetes\n* Current (or within the last 4 weeks prior to study start) use of probiotic supplementation.\n* Immobile (defined as the inability to participate in all study-related procedures)\n* History of complicated gastrointestinal surgery\n* Diagnosed with inflammatory bowel disease (IBD)\n* Current diagnosis of psychiatric disease\u002Fs or syndromes\n* Current diagnosis of neurodegenerative disease\n* Systemic use of antibiotics and\u002For steroid medication in the last 4 months prior to inclusion\n* Use of any non-steroidal anti-inflammatory drug (NSAID) more than 3 times a week for the last 2 months\n* Consumption of any NSAID within 7 days of study start\n* Any condition which could substantially interfere with intestinal barrier function (e.g. gluten sensitivity, lactose intolerance, celiac disease, IBS, IBD) or in any other way with the outcome of the study, as decided by the principal investigator's discretion\n* Regular smoking, use of snuff, nicotine, cannabidiol narcotics\u002Fsupplements, or e-cigarette use\n* Drinking more than 9 standard cups of alcohol per week and\u002For more than 3 standard cups of alcohol per occasion\n* Regular use, for more than three times a week for the last 2 months and\u002For 7 days prior to inclusion, of medications which, according to the principal investigator, can have an anti-inflammatory effect or affect in any way the intestinal barrier function or have an impact on the study analysis (such as laxatives, anti-diarrheal, anti-cholinergic, etc.)\n* After being included in the study, starting any medication or treatment that could potentially influence the study participation and\u002For study analysis.",true,"25 Years","65 Years",{"count":62,"type":21},50,[64],"PHASE1","The aim of this study is to determine whether encapsulation of probiotic bacteria using natural plant protein can enhance bacterial colonisation. Lactobacillus rhamnosus is an ideal strain for the intervention, as it has been shown to affect overall gut health, gut-brain axis, and brain function.\n\nTwenty-five participants aged 25 to 65 years will be recruited and assessed on four occasions to compare the blood and faecal effects of a 28-day ingestion of a yoghurt beverage with and without the probiotic strain of interest. The study window will be 70+\u002F13 days.\n\nThe current study will provide important information on the physiological function of probiotics in the small bowel. Understanding the underlying physiological effects of targeted probiotic delivery to the intestine and the impact on the microbiome is important for health outcomes.",[67,28],"Colonization, Asymptomatic",[69,70,71,72],"Probiotic","Microbiota","Colonization","Dairy","2026-05-05",{"date":75,"type":42},"2026-05-08",{"date":77,"type":21},"2026-04",{"date":79,"type":21},"2026-08",{"name":81,"class":49},"University College Dublin"]